Patents by Inventor Pascal Furet

Pascal Furet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Organic compounds
    Patent number: 8940771
    Abstract: The present invention relates to compounds of formula I and its salts, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: January 27, 2015
    Assignee: Novartis AG
    Inventors: Giorgio Caravatti, Robin Alec Fairhurst, Pascal Furet, Vito Guagnano, Patricia Imbach
  • BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
    Publication number: 20150025059
    Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Applicant: Novartis AG
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingswood, Pascal Furet, Vikki Furminger, Diana Janus, Sarah Lewis, Jon Christopher Loren, Valentina Molteni, Alex Michael Saunders, Duncan Shaw, Lilya Sviridenko, Christopher Thomson, Ryan West, Vince Yeh
  • OXAZOLIDIN-2-ONE COMPOUNDS AND USES THEREOF
    Publication number: 20140378450
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Application
    Filed: September 5, 2014
    Publication date: December 25, 2014
    Applicant: Novartis AG
    Inventors: Giorgio CARAVATTI, Robin Alec FAIRHURST, Pascal FURET, Clive MCCARTHY, Heinrich RUEEGER, Frank Hans SEILER, Frédéric STAUFFER
  • Pyrazolopyrrolidine Compounds
    Publication number: 20140350010
    Abstract: The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Application
    Filed: November 28, 2012
    Publication date: November 27, 2014
    Applicant: NOVARTIS AG
    Inventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Robert Mah, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel
  • COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1
    Publication number: 20140343086
    Abstract: The present invention relates to compounds of formula (I): in which Y, Y1, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.
    Type: Application
    Filed: July 31, 2014
    Publication date: November 20, 2014
    Applicant: NOVARTIS AG
    Inventors: Stephanie Kay DODD, Pascal FURET, Robert Martin GROTZFELD, Wolfgang JAHNKE, Darryl Brynley JONES, Paul William MANLEY, Andreas MARZINZIK, Xavier Francois Andre PELLE, Bahaa SALEM, Joseph SCHOEPFER
  • IMIDAZOPYRROLIDINONE COMPOUNDS
    Publication number: 20140343084
    Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Application
    Filed: July 10, 2014
    Publication date: November 20, 2014
    Inventors: Pascal FURET, Vito GUAGNANO, Philipp HOLZER, Joerg KALLEN, Lv LIAO, Robert MAH, Liang MAO, Keiichi MASUYA, Achim SCHLAPBACH, Stefan STUTZ, Andrea VAUPEL
  • NOVEL PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
    Publication number: 20140336166
    Abstract: The invention relates to PI3K inhibitors of the formula (I) • in which all of the variables are as defined in the specification, to their preparation, to their medical use, in particular to their use in the treatment of cancer and neurodegenerative disorders, and to medicaments comprising them.
    Type: Application
    Filed: October 26, 2012
    Publication date: November 13, 2014
    Applicant: NOVARTIS AG
    Inventors: Emmanuelle Briard, Pascal Furet, Andreas Lerchner, Peter Meier, Branko Radetich, David Andrew Sandham, Yanyi Zhu
  • Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
    Patent number: 8883819
    Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: November 11, 2014
    Assignees: IRM LLC, Novartis AG
    Inventors: Ian Bruce, Sylvie Chamoin, Stephen Paul Collingwood, Pascal Furet, Vikki Furminger, Diana Janus, Sarah Lewis, Jon Christopher Loren, Valentia Molteni, Alex Michael Saunders, Duncan Shaw, Lilya Sviridenko, Christopher Thomson, Ryan West, Vince Yeh
  • Oxazolidin-2-one compounds and uses thereof
    Patent number: 8865894
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: October 21, 2014
    Assignee: Novartis AG
    Inventors: Giorgio Caravatti, Robin Alec Fairhurst, Pascal Furet, Frédéric Stauffer, Frank Hans Seiler, Clive McCarthy, Heinrich Rueeger
  • Hydroxy substituted isoquinolinone derivatives
    Patent number: 8859535
    Abstract: The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: October 14, 2014
    Assignee: Novartis AG
    Inventors: Nicole Buschmann, Pascal Furet, Philipp Holzer, Joerg Kallen, Keiichi Masuya, Stefan Stutz
  • Cyclohexyl isoquinolinone compounds
    Patent number: 8859586
    Abstract: The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: October 14, 2014
    Assignee: Novartis AG
    Inventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Keiichi Masuya, Stefan Stutz
  • CYCLOHEXYL ISOQUINOLINONE COMPOUNDS
    Publication number: 20140275158
    Abstract: The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Application
    Filed: June 19, 2012
    Publication date: September 18, 2014
    Applicant: Novartis AG
    Inventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Keiichi Masuya, Stefan Stutz
  • Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
    Patent number: 8829195
    Abstract: The present invention relates to compounds of formula (I): in which Y, Y1, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: September 9, 2014
    Assignee: Novartis AG
    Inventors: Stephanie Kay Dodd, Pascal Furet, Robert Martin Grotzfeld, Wolfgang Jahnke, Darryl Brynley Jones, Paul William Manley, Andreas Marzinzik, Xavier Francois Andre Pelle, Bahaa Salem, Joseph Schoepfer
  • Quinazoline Derivatives
    Publication number: 20140249139
    Abstract: The invention relates to substituted quinazoline derivative of the formula (I), wherein A, X1, X2, X3, X4 and R5 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: October 19, 2012
    Publication date: September 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Pascal Furet, Christina Hebach, Klemens Hogenauer, Gregory Hollingworth, Ian Lewis, Alexander Baxter Smith, Nicolas Solvermann, Frederic Stauffer, Romain Wolf, Frederic Zecri
  • SALT FORMS OF BICYCLIC HETEROCYCLIC DERIVATIVES
    Publication number: 20140249177
    Abstract: The present invention provides novel solid forms of pharmaceutically active agents and therapeutic uses thereof. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: February 21, 2014
    Publication date: September 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Ian BRUCE, Sylvie CHAMOIN, Stephen Paul COLLINGWOOD, Pascal FURET, Vikki FURMINGER, Sarah LEWIS, Jon Christopher LOREN, Lin LV, Valentina MOLTEN, Alex Michael SAUNDERS, Duncan SHAW, Roy Maxwell TURNER, Vince YEH
  • 3-Methyl-imidazo[1,2-b]pyridazine derivatives
    Patent number: 8822468
    Abstract: The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: September 2, 2014
    Assignee: Novartis AG
    Inventors: Pascal Furet, Clive McCarthy, Joseph Schoepfer, Carsten Spanka, Melanie Stang, Frederic Stauffer
  • Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
    Patent number: 8815926
    Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: August 26, 2014
    Assignee: Novartis AG
    Inventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Lv Liao, Robert Mah, Liang Mao, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel
  • Quinoline carboxamide derivatives as protein tyrosine kinase inhibitors
    Patent number: 8815901
    Abstract: The invention relates to compounds of formula (I) wherein the substituents are as defined in the specification, in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof; processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: August 26, 2014
    Assignee: Novartis AG
    Inventors: Pascal Furet, Diana Graus Porta, Vito Guagnano
  • PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES
    Publication number: 20140186469
    Abstract: The present invention relates to a compound of formula (I) or a salt thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.
    Type: Application
    Filed: February 27, 2014
    Publication date: July 3, 2014
    Applicant: NOVARTIS AG
    Inventors: Robin Alec Fairhurst, Vito Guagnano, Patricia Imbach-Weese, Giorgio Caravatti, Pascal Furet
  • Pyrirnidinyl aryl urea derivatives being FGF inhibitors
    Patent number: 8759517
    Abstract: The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: June 24, 2014
    Assignee: Novartis AG
    Inventors: Guido Bold, Pascal Furet, Vito Guagnano